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(236/296). The total duration of treatment was restricted
to 48 hours for 360 of 366 (98%) patients. Global con-
formity, defined as the combination of the five major cri-
teria, accounted for 52% (201/386) of patients undergo-
ing THR surgery. After multivariate analysis, a statistically
significant association was found between the global con-
formity and the prescribers (p  0.03). The interventions
during 1999 (AOR 0.61; 95% CI 0.40–0.92) were associ-
ated with a risk of non-conformity. Adherence to guide-
lines for antibiotic prophylaxis practice was not associated
with prescriber’s characteristics.
CONCLUSIONS: Although French guidelines were re-
cently published, the appropriateness of antibiotic pro-
phylaxis in THR surgery could still be enhanced espe-
cially in terms of the rational choice of a molecule and
timing of the first injection.
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PROPHYLAXIS AGAINST RSV, VARICELLA 
AND PNEUMOCOCCAL INFECTIONS:
ECONOMIC-BASED DECISION-MAKING
Strutton DR, Stang PE
Galt Associates, Sterling, VA, USA
OBJECTIVE: To facilitate evaluation and comparison of
cost-effectiveness results for varicella and pneumococcal
conjugate vaccination with respiratory syncytial virus
(RSV) prophylaxis using palivizumab by standardizing
cost and benefit results from published studies.
METHODS: MEDLINE search identified English lan-
guage cost-effectiveness studies for the three interven-
tions. Prophylaxis recommendations by the American
Academy of Pediatrics were examined. Results were dis-
counted by 5% and costs were inflated to 1997 dollars
using the Medical Care component of the CPI.
RESULTS: From the societal perspective, the cost per life
year saved was $144,000 for pneumococcal vaccine and
$54,000 for palivizumab RSV prophylaxis, but varicella
vaccine saved money. From the payers’ perspective, the
cost per life year saved was $278,000 for pneumococcal
vaccine, $55,000 for RSV prophylaxis and $23,000 for va-
ricella vaccine. Payers’ cost to avoid hospitalization for
RSV infection was $13,000. An avoided varicella case cost
$6 and it cost $2400 to avoid a major varicella sequela,
and each case of pneumococcus avoided cost $103,000.
CONCLUSION: Prevention of avoidable childhood mor-
bidity and mortality may cause incremental costs to payers
but would be a rational policy from a societal point of view.
Costs associated with RSV prophylaxis of high-risk infants
with palivizumab do not appear unreasonable compared
with the cost-effectiveness of two recent vaccines recom-
mended for universal use in healthy children in the US.
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OBJECTIVE: The Recurrent Genital Herpes Quality of
Life questionnaire (RGHQoL) is a needs-based quality of
life (QoL) instrument specifically for use with recurrent
genital herpes (RGH). It has been shown to have excel-
lent psychometric properties. However, it cannot cur-
rently be used in the calculation of utility for economic
analyses. Existing utility instruments cover symptoms
and functioning, rather than QoL. Concern has been ex-
pressed over their relevance for RGH and, consequently,
their ability to show differences between interventions.
The aim of this project is to explore the potential for us-
ing the RGHQoL to produce meaningful utility scores.
The first stage was to investigate whether a preference
elicitation exercise was required or whether RGHQoL re-
sponses could be incorporated directly into utility analy-
ses. This paper presents findings from the first stage.
METHODS: Structured interviews were conducted with
100 RGH patients. Patients undertook preference exer-
cises (paired comparison and ranking) with six RGHQoL
items and completed the RGHQoL. Thurstone’s law of
comparative judgement was used to calculate item prefer-
ence weights. These were compared with item severity
weights derived via application of the Rasch model to
RGHQoL responses.
RESULTS: Item ordering of severity was: B-E-D-C-A-F
(paired comparisons), B-C-D-E-A-F (ranking) and F-A-D-
C-E-B (Rasch severity). The paired comparisons and
ranking exercises resulted in different ordering of some
items, even though the methods are considered direct al-
ternatives for eliciting preference information. The Rasch
severity and preference weights provided very different
orderings. For example, the most severe item according
to patients’ responses to the RGHQoL was judged the
least severe in the paired comparison and ranking situa-
tions.
CONCLUSIONS: The results suggest that individuals’
ratings of what would have the most impact on them are
very different from what actually has an impact. RGHQoL
responses cannot be used directly in place of preference
elicitation.
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OBJECTIVES: This paper reports on the development of
and psychometric validation of the Influenza Daily Dis-
ruption Questionnaire (IDDQ), a short new instrument
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to measure the disruptive effects of influenza on daily ac-
tivities.
METHODS: People with a previous influenza episode were
recruited by newspaper advertisement to discuss the effects
of influenza on their daily activities using a semi-structured
interview technique. Each interview was transcribed, and
a list of statements was generated via content analysis. A
draft instrument was then developed for pilot testing. A
cognitive debrief was included as part of the pilot test to
gain a better understanding of patient’s evaluation of the
adequacy and relevance of the questionnaire. The final
IDDQ was then produced. The IDDQ was administered
in a clinical trial of influenza treatment. The psychomet-
ric properties of the instrument will be reported.
RESULTS: Twelve respondents were interviewed for the
drafting of the IDDQ, while another ten were used in
the pilot testing of the draft eight-item instrument. On
the basis of the pilot testing, one item was re-ordered,
five items were slightly re-worded, and two items were
left unchanged. The final version of the IDDQ has eight
items, each relating to the effects of influenza on disrup-
tion of specific daily activities: self-care; shopping; house-
work; care for others; exercise; social life; hobbies, and
work/school/college. Each item is scored on a five-point,
Likert-type response scale, rated attitudinally from com-
pletely agree to completely disagree.
CONCLUSION: This paper describes the successful de-
velopment of a multi-item questionnaire to measure the
effects of influenza on disruption of daily activities. Psy-
chometric properties of the IDDQ will be presented.
KIDNEY & URINARY DISEASE
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OBJECTIVE: To compare the cost-effectiveness (CE) of
three competitive surgical procedures for female stress
urinary incontinence (SUI). The three procedures are ret-
ropubic urethral suspension (Burch), urethral sling, and a
new procedure using SURx technology. The study popu-
lation consists of women aged 18 to 85 years who have a
confirmed diagnosis of type I or type II genuine SUI and a
planned surgical treatment procedure. The perspective of
commercial third-party payers is taken for this study.
METHODS: A decision model was developed to com-
pare the costs and effectiveness of the three treatment
strategies for SUI. A hypothetical woman in the study
population is treated with one of the three treatment al-
ternatives and tracked over a period of 12 months. The
CE ratio was defined as cost per cure. Only direct medi-
cal costs were included and estimated by charge data (in
year 2000 dollars). The costs, effectiveness, and outcome
probabilities were collected from InPatientView, the
HCUP Nationwide Inpatient Sample, HCCA Physician
Fee & Coding Guide, the literature, SURx clinical trials,
and expert’s suggestions.
RESULTS: The SURx procedure has the lowest costs
($11,757.22) and the highest effectiveness (0.94). The CE
of the SURx, Burch, and Sling procedures was $12,539.70,
$13,167.85, and $13,736.07 per cure, respectively. Burch
and Sling procedures were dominated by SURx treatment.
The incremental CE of Sling was $52,310.61 per additional
cure relative to Burch. The CE ratio was sensitive to the
hospital and physician costs of each procedure and the
SURx cure rate. The threshold value of the SURx cure rate
was 62%.
CONCLUSIONS: SURx technology for treatment of women
with type I or II genuine SUI is the most cost-effective treat-
ment option as compared to the Burch and Sling proce-
dures. Therefore, SURx may be an appropriate first-line
therapy for SUI.
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OBJECTIVE: An economic model was developed to esti-
mate the comparative cost-effectiveness of treating unstable
bladder (UB) with tolterodine immediate-release (2mg bid),
oxybutynin (5mg bid) and “no treatment” in Italy. The
model uses a one-year timeframe and the payer perspective.
METHODS: The treatment population was based on the
percentage of patients seeking treatment in Italy. The treat-
ment population was divided into successfully treated pa-
tients (STP) and patients failing treatment (PFT). The per-
centage of STP was calculated from clinical efficacy adjusted
by annual persistency. For each group of patients, five cat-
egories of costs were identified: drug costs; incontinence
pads; physician visits; lab tests/diagnostics, and associ-
ated comorbidities. Resource utilization and costs were
obtained from the National Health Service, diagnostic
and hospital codes (diagnostic related groups) and expert
medical panels.
RESULTS: The prevalence of UB sufferers in Italy is esti-
mated to be 12% in 2001 (approximately 7 million peo-
ple), with only 23% of those patients seeking treatment.
STP use fewer pads per day, visit physicians more fre-
quently, have fewer lab tests/diagnostics, and experience
fewer comorbidities than PFT. Efficacy is similar between
tolterodine and oxybutynin. Persistence on therapy is
higher for tolterodine compared to oxybutynin (70% for
tolterodine, 19% for oxybutynin). As a result, effective-
ness is higher for tolterodine than for oxybutynin (42%
for tolterodine, 9.5% for oxybutynin, and 0% for “no
